
Pathologists and Pathology: All About These Specialists
Pathology is the study of diseases, their causes, their progression, and their effect on the human body. The name comes from the Greek word 'pathología,' which means 'suffering.'
In the context of pathology, 'disease' is any deviation from a set of observable characteristics of an individual resulting from the interaction of their genes with their environment. This deviation is quantified and measured via symptoms reported by the person experiencing them, as well as signs measured through tests by a pathologist.
The cause of the disease is referred to as its etiology. Disease develops through a series of chemical or cellular reactions, which a pathologist studies and investigates.
Learn more about the role of a pathologist below.
What does a pathologist do?
A pathologist analyzes tissues, cells, and bodily fluids. They are an important part of a medical professional team, often tasked with answering important questions about disease, such as:
'What is it?' (a diagnosis)
'How is it going to behave?' (a prognosis)
'How should it be treated?' (treatment strategy)
Pathologists make this determination by looking at the cellular, chemical, and mechanical behavior of body and its tissues, using their observations, the results of tests they perform, and newly developed computing technologies.
These medical doctors specialize in looking at human tissue, blood, urine, and other bodily fluids under a microscope. Oftentimes, they work in the background without speaking to patients.
According to a paper published in 2020, the role of pathologists in medical research and treatment is growing as the human genome is deciphered, and as complex interactions of cellular biochemistry are refined and the risk of disease is more accurately calculated.
What are the types of pathology
There are several sub-specialties of pathology, and these medical specialists usually focus on one to several types.
Blood banking and transfusion: This type of pathologist maintains an adequate blood supply, blood donor and recipient safety, and appropriate blood use at a medical facility. They direct the preparation and safe use of specially prepared blood components, including red blood cells, white blood cells, platelets and plasma constituents, and bone marrow or stem cells for transplantation.
Clinical pathology: A clinical, or chemical, pathologist specializes in the biochemistry of the human body to understand disease diagnosis and progression. They monitor substances in bodily fluids like blood and urine to assess changes in someone's body.
Clinical informatics: These specialists evaluate data, health trends, and communication systems and use this information to improve medical processes that will allow for better patient outcomes. Think of them as the quality control of pathology.
Cytopathology: This type of pathology is the study of individual cells of the body. The human body is made up of millions of cells that can be looked at under the microscope to help diagnose medical conditions. It's often used to diagnose cancer, other conditions of the respiratory, urinary, and gastrointestinal tracts, and thyroid gland, salivary glands, and lymph nodes.
Dermatopathology: This discipline specializes in human skin diseases. It involves the microscopic examination, description, and interpretation of biopsy specimens. Dermatopathologists often have training in dermatology.
Forensic pathology: This is the study of tissue or bodily fluid in a person after their violent, sudden, and unexpected death. Forensic pathologists are sometimes also medical examiners or coroners, performing autopsies for a government law enforcement agency. Their job is to identify the cause and manner in which someone died.
Hematopathology: A hematologist studies conditions specific to blood cells, blood clotting, bone marrow, and lymph nodes. They use blood samples to diagnose conditions like anemia and blood cancers.
Medical microbiology: This discipline specializes in infectious organisms and diseases. They take part in the work to prevent, diagnose, and treat conditions that result from microorganisms.
Molecular genetic pathology: This type of specialist expert investigates gene structure, function, and mutations. They use laboratory testing to help diagnose, treat, and provide a prognosis for people with genetic disorders, infectious diseases, and human development. They also help determine the risk of genetic disorders.
Neuropathology: Neuropathologists study conditions that affect the nervous system and skeletal muscles. They often work with neurologists and neurosurgeons to diagnose neurological diseases, and also analyze tissue samples following death to study dementia, assess trauma, and evaluate genetic conditions.
Surgical pathology: This is the study of the tissues removed during surgery —such as a tumor—to help diagnose a disease and determine a treatment plan. This can sometimes occur while a surgery is ongoing, and can inform surgeons on how to proceed.
Pediatric pathology: This type of pathology involves the research of conditions that occur during fetal growth, infancy, and child development. Pediatric pathologists investigate diseases in children up to 18 years of age.
How much education and training is required of pathologists?
In order to become a pathologist in the United States, a medical professional starts with a four-year undergraduate degree, often in chemistry or biology. Next is a four-year doctorate degree in medicine, either for a doctor of medicine (MD) or doctor of osteopathic medicine (DO).
This is followed by a medical residence in a medical facility, which for pathology usually lasts for three years. Combined residencies in both anatomical and clinical pathology can take four years or longer.
In all, the process can take 11 years or longer.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
8 minutes ago
- Associated Press
Vanessa Colella Appointed as President and Chief Executive Officer of Blue Shield of California Sister Company, Stellarus
Colella takes the helm at the newly-formed healthcare technology company that aims to modernize health plans via its artificial intelligence-driven technology innovation platform OAKLAND, Calif., July 30, 2025 /PRNewswire/ -- Stellarus today announced that Vanessa Colella, who previously held global leadership roles in innovation and digital partnerships at Visa and Citi, has been appointed to serve as the healthcare technology company's President and Chief Executive Officer. 'It's my pleasure to welcome Vanessa to Stellarus and the Ascendiun family of companies,' said Paul Markovich, President and Chief Executive Officer of Ascendiun. 'With Vanessa's experience working at the intersection of technology, financial services, and media, I am confident that she will boldly lead the development of the unique solutions we need in health care. Her strategic, pragmatic, and collaborative approach to innovation and getting work done at a rapid pace is just what Stellarus needs.' In January 2025, Blue Shield of California announced the creation of Ascendiun, a non-profit parent company that oversees Blue Shield of California, Altais, and Stellarus. Veteran health plan CEO Paul Markovich took the reins of the parent company and served as interim President at Stellarus until Vanessa assumed the role this week. As a global leader in the financial services industry, Colella is experienced in meeting consumers' needs for simpler, real-time, and transparent experiences. Most recently, she directed the development and commercialization of Visa's digital-first products and services as their Global Head of Innovation and Digital Partnerships. Colella also oversaw Visa's global network of Innovation Centers. As Citi's Chief Innovation Officer, she leveraged the power of process simplification, operating model redesign, and new technologies to drive growth and innovation across Citi's businesses, clients, and partners. 'We need health care to move at the speed we expect as digital consumers,' said Vanessa Colella. 'At Stellarus, we have a tremendous opportunity to move past incremental change in this industry and work with health plans to drive meaningful outcomes for their members.' Stellarus partners with health plans, which will leverage its unique technology innovation platform to help drive administrative cost savings, reduce the cost of healthcare trend, increase member and provider net promoter scores, and uphold quality targets – vastly improving efficiency and affordability. Through their partnership with Stellarus, health plans are able to maintain their local independence, continuing to focus their resources and expertise on improving the long-term health of their communities, while also modernizing their business operations and driving down the cost of health care. 'I am thrilled to work with the Stellarus team as we reimagine how advanced technologies and artificial intelligence can be applied to help health plans and members move forward with affordable and effective care,' said Colella. 'Expect some big and exciting news from Stellarus in the coming months.' About Stellarus Part of the Ascendiun family of companies, which includes Blue Shield of California and Altais, Stellarus is a healthcare technology company that aims to drive measurable outcomes for health plans with products and services built and delivered via its technology innovation platform. Stellarus' unique technology model is designed to enable plans to automate and improve operations, reduce costs, and enhance member experiences. We're changing the status quo by empowering health plans to create a healthcare experience worthy of their family, friends and neighbors. View original content to download multimedia: SOURCE Stellarus


Associated Press
8 minutes ago
- Associated Press
NeuralBase to Acquire HeartEase, Set to Revolutionize Enterprise Wellness and Preventive Health Diagnostics
LAS VEGAS, NV - July 30, 2025 ( NEWMEDIAWIRE ) - NeuralBase AI Ltd. (OTC: NBBI), operating under its enterprise brand BMP AI and a growing innovator in enterprise artificial intelligence, is pleased to announce that it has executed an agreement to acquire HeartEase, a cutting-edge AI-powered diagnostic platform that uses smartphone microphones to detect early signs of heart abnormalities. This strategic acquisition marks a bold step in NeuralBase's mission to integrate wellness-focused, preventive healthcare solutions into its enterprise AI chatbot ecosystem. With rising demand from corporations and institutions for integrated employee wellness solutions, NeuralBase recognized a growing gap in tools that go beyond mental health chatbots and provide actionable health diagnostics. HeartEase fills this need by enabling non-invasive, accessible, and real-time heart health screening through mobile devices - a perfect complement to BMP AI's enterprise-focused chatbot technology. 'We believe that HeartEase will become a revolutionary platform as it harnesses the power of artificial intelligence and mobile technology to provide early detection of heart abnormalities. Unlike traditional diagnostics, it requires no external hardware - only a smartphone,' stated Vighnesh Dobale, CEO of NeuralBase. Key Features of HeartEase are expected to include: This targeted acquisition represents a transformational shift in how enterprises can care for their workforce. BMP AI's chatbot platform already supports companies with intelligent task automation, HR interactions, and employee engagement tools. The addition of HeartEase allows enterprises to take employee care to a whole new level by integrating preventive health screening into the daily digital experience - right on employees' smartphones. 'With HeartEase, we're not just improving enterprise chatbot functionality - we're redefining how technology can protect and empower people in their everyday lives,' added Dobale. 'We see this as the foundation for a broader wellness initiative that supports both mental and physical health across global workplaces.' The backend AI engine of HeartEase is already fully trained using validated clinical datasets, and mobile integration is underway. A Minimum Viable Product (MVP) is slated for rapid field testing in Q4 2025, with pilots targeting enterprise clients, wellness programs, and rural health campaigns. As businesses increasingly recognize the ROI of employee wellness, from lower healthcare costs to higher productivity and retention, NeuralBase's acquisition of HeartEase is set to deliver a unique competitive edge. It places the company at the forefront of AI-driven preventive healthcare, bridging the gap between enterprise tech and real-world impact. With this move, NeuralBase continues its commitment to building technologies that scale ethically, inclusively, and intelligently, transforming how companies operate. The closing of the transaction is subject to the completion of customary due diligence and the satisfaction of other closing conditions. NeuralBase will provide further updates if and when available. Additional information about the Company is available at or by visiting About NEURALBASE AI LTD. NeuralBase AI Ltd. (OTC: NBBI) is an AI company developing secure, scalable, and context-aware conversational agents and workflow automation systems. Through its BMP AI platform - now in beta testing - the company enables organizations to streamline internal operations, enhance team collaboration, and increase productivity while maintaining strict compliance and data integrity. Legal Disclaimer and Forward-Looking Statements This press release contains forward-looking statements as defined under Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These statements are based on current expectations, estimates, projections, and assumptions made by NeuralBase AI Ltd. (the 'Company' or 'NBBI') in light of experience, current conditions, anticipated future developments, and other factors. Forward-looking statements may include words such as 'aims,' 'anticipates,' 'believes,' 'plans,' 'expects,' 'intends,' 'will,' 'may,' 'could,' 'should,' and similar expressions. These statements relate to, among other things, the expected performance and capabilities of the BMP AI platform; the Company's ability to successfully complete product development, enter commercial deployment, or scale its technology; future revenues and market expansion; and general strategic direction. All such statements are inherently uncertain and involve a number of risks that could cause actual results to differ materially from those expressed or implied in any forward-looking statement. NeuralBase AI Ltd. is a fully reporting company with the U.S. Securities and Exchange Commission (SEC) and files annual and quarterly reports, current reports, and other required disclosures. All public filings and disclosures may be reviewed at the SEC's EDGAR database at The Company trades on the OTC Markets under the ticker symbol NBBI. This press release is not, and should not be construed as, an offer to sell or a solicitation of an offer to buy any securities of NeuralBase AI Ltd. in the United States or in any other jurisdiction. Offers and sales of securities, if any, will be made only pursuant to an effective registration statement or valid exemption under the U.S. Securities Act of 1933, as amended. Investing in securities traded on the OTC Markets involves significant risk, including potential loss of principal, low liquidity, high volatility, and limited publicly available information. Shares traded on the OTC Markets may be more susceptible to market manipulation or price swings. Investors are strongly advised to conduct their own due diligence, consult a qualified investment advisor, and carefully review all SEC filings prior to making any investment decision. Media Contact: Vighnesh Dobale Chief Executive Officer [email protected] (727) 314-3717 View the original release on


Medscape
36 minutes ago
- Medscape
Trends in Antiseizure Drug Use During Pregnancy
TOPLINE: Prenatal exposure to safer antiseizure medications (ASMs) increased and valproate use decreased, but the use of newer medications with uncertain risks surged. METHODOLOGY: Researchers analysed 55,801 ASM-exposed pregnancies (from 2013 to 2021) out of 8,669,502 total pregnancies documented in the French National Mother-Child Register. ASMs were categorised into three safety tiers: those considered the safest (lamotrigine and levetiracetam), those with uncertain risk (pregabalin, gabapentin, clonazepam, oxcarbazepine, and newer ASMs), and those with acknowledged risk (valproic acid, valpromide, carbamazepine, topiramate, phenobarbital, phenytoin, and primidone). The maternal age was 15-49 years; socioeconomic status was assessed via health insurance, and diagnoses were confirmed using the International Statistical Classification of Diseases and Related Health Problems, 10th Revision codes. Maternal and pregnancy characteristics, along with ASM treatment characteristics, were analysed over the study period (2013-2021) and by subperiods (2013-2015, 2016-2018, and 2019-2021). The outcome was the temporal change in prenatal ASM exposure rates across safety categories, analysed on the basis of year, diagnosis, and social indicators. TAKEAWAY: Between 2013 and 2021, prenatal exposures to valproic acid and valpromide declined by 84% and 89%, respectively, but terminations rose (+23% and +28%, respectively), and multiple valproate dispensations and sustained live birth exposures fell drastically (valproic acid: -86% and -91% and valpromide: -93% and -96%, respectively). The use of the safest ASMs (lamotrigine and levetiracetam) rose by +30%. The use of ASMs with uncertain risks rose by +33%, notably pregabalin (+49%), gabapentin (+27%), and newer ASMs (+140%). The use of carbamazepine and topiramate decreased to a lesser extent (-40% and -34%, respectively), with nearly 600 newborns exposed to each of these medications between 2019 and 2021; among women with a low level of resources, exposure to ASMs with uncertain or acknowledged risks was higher (18.5% and 17.9%, respectively) than exposure to the safest ASMs or unexposed (13.8% and 13.5%, respectively). Lamotrigine use linked to mood disorders rose by +51%, correlating with a +35% rise in termination rates. Terminations also rose with ASMs with acknowledged risks. IN PRACTICE: "Additional measures are needed to further reduce perinatal exposure to ASMs with acknowledged or uncertain risks, especially among the most socially deprived populations," the authors wrote. SOURCE: This study, led by Pouneh Shahriari, EPI-PHARE Scientific Interest Group in Epidemiology of Health Products (French National Agency for the Safety of Medicines and Health Products, French National Health Insurance), Saint-Denis, France, was published online on July 23, 2025, in Neurology. LIMITATIONS: This study was limited by the reliance on prescription claims to determine exposure to ASMs and the absence of data on clinical indications for treatment. However, prior research using this dataset supports its reliability for assessing prenatal exposure to ASMs. DISCLOSURES: This study did not report any targeted funding. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.